These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 19275276)

  • 21. Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder.
    Oki T; Kageyama A; Takagi Y; Uchida S; Yamada S
    J Urol; 2007 Feb; 177(2):766-70. PubMed ID: 17222678
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evolution of transdermal oxybutynin in the treatment of overactive bladder.
    Sahai A; Mallina R; Dowson C; Larner T; Khan MS
    Int J Clin Pract; 2008 Jan; 62(1):167-70. PubMed ID: 18173821
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patient-selected goals in overactive bladder: a placebo controlled randomized double-blind trial of transdermal oxybutynin for the treatment of urgency and urge incontinence.
    Cartwright R; Srikrishna S; Cardozo L; Robinson D
    BJU Int; 2011 Jan; 107(1):70-6. PubMed ID: 20626389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder.
    Abrams P; Freeman R; Anderström C; Mattiasson A
    Br J Urol; 1998 Jun; 81(6):801-10. PubMed ID: 9666761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial.
    Sand PK; Goldberg RP; Dmochowski RR; McIlwain M; Dahl NV
    Am J Obstet Gynecol; 2006 Dec; 195(6):1730-5. PubMed ID: 17132474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity.
    Cartwright PC; Coplen DE; Kogan BA; Volinn W; Finan E; Hoel G
    J Urol; 2009 Oct; 182(4):1548-54. PubMed ID: 19683731
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oxybutynin and the overactive bladder.
    Andersson KE; Chapple CR
    World J Urol; 2001 Nov; 19(5):319-23. PubMed ID: 11760780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oxybutynin for treatment of urge urinary incontinence and overactive bladder: an updated review.
    Abramov Y; Sand PK
    Expert Opin Pharmacother; 2004 Nov; 5(11):2351-9. PubMed ID: 15500382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retrospective evaluation of outcomes in patients with overactive bladder receiving tolterodine versus oxybutynin.
    Jumadilova Z; Varadharajan S; Girase P; Ollendorf DA
    Am J Health Syst Pharm; 2006 Dec; 63(23):2357-64. PubMed ID: 17106009
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
    Cardozo L; Thorpe A; Warner J; Sidhu M
    BJU Int; 2010 Aug; 106(4):506-14. PubMed ID: 20132203
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence.
    Dmochowski RR; Davila GW; Zinner NR; Gittelman MC; Saltzstein DR; Lyttle S; Sanders SW;
    J Urol; 2002 Aug; 168(2):580-6. PubMed ID: 12131314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.
    Kennelly MJ; Lemack GE; Foote JE; Trop CS
    Urology; 2009 Oct; 74(4):741-5. PubMed ID: 19628264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Once-daily oxybutynin patch improves nocturia and sleep quality in Japanese patients with overactive bladder: Post-hoc analysis of a phase III randomized clinical trial.
    Yokoyama O; Yamaguchi A; Yoshida M; Yamanishi T; Ishizuka O; Seki N; Takahashi S; Yamaguchi O; Higo N; Minami H; Masegi Y
    Int J Urol; 2015 Jul; 22(7):684-8. PubMed ID: 25782032
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions.
    Staskin DR; Rosenberg MT; Dahl NV; Polishuk PV; Zinner NR
    Int J Clin Pract; 2008 Jan; 62(1):27-38. PubMed ID: 17983434
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transdermal oxybutynin in the treatment of overactive bladder.
    Davila GW
    Clin Interv Aging; 2006; 1(2):99-105. PubMed ID: 18044106
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transdermal oxybutynin: a review.
    Shaw GL; Patel HR
    Expert Opin Drug Metab Toxicol; 2007 Jun; 3(3):435-9. PubMed ID: 17539749
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transdermal oxybutynin: sticking to the facts.
    Cartwright R; Cardozo L
    Eur Urol; 2007 Apr; 51(4):907-14; discussion 914. PubMed ID: 17157979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Considering the prominent complaint as a guide in medical therapy for overactive bladder syndrome in women over 45 years.
    Jafarabadi M; Jafarabadi L; Shariat M; Rabie Salehi G; Haghollahi F; Rashidi BH
    J Obstet Gynaecol Res; 2015 Jan; 41(1):120-6. PubMed ID: 25369726
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial.
    Homma Y; Paick JS; Lee JG; Kawabe K;
    BJU Int; 2003 Nov; 92(7):741-7. PubMed ID: 14616458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cognitive function assessment in elderly patients with overactive bladder treated with transdermal oxybutynin.
    Müller-Arteaga C; Batista-Miranda JE; Zubiaur Libano C; El Khoury Moreno R; Morales Solchaga G; Casas Nebra J; Leva Vallejo M; Gonzalez Garcia O; Errando-Smet C; Arlandis-Guzman S
    Actas Urol Esp (Engl Ed); 2019 Apr; 43(3):143-150. PubMed ID: 30470585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.